Technology Bundle ID: TAB-978

Anti-Vaccinia Monoclonal Antibody

Request More Info
Licensing Contact:
Primary Inventors: 
Jonathan (Jon) Yewdell (NIAID)
Therapeutic Area: 
Infectious Disease
Application: 
Research Materials
Institute or Center: 
NIAID

The current technology describes a monoclonal antibody that reacts with a vaccinia virus protein abundantly expressed under an early viral promoter after infection of cells. The antibody is useful for quantitating vaccinia virus infected cells and for studying the function of the protein to which it binds, which is known to be a double stranded RNA binding protein involved in resistance of the virus to interferons. This antibody is available for licensing through a biological materials license agreement.

Patents

EIR Application

Research Material – Patent protection is not being pursued for this technology

Updated

Sep 1, 2004

Data Source: 
tts